ArticleIndian journal of surgical oncology2024
Natural Orifice Trans-oral, Trans-vestibular Endoscopic Thyroidectomy (NO-TOTVET): a Case Series.
Article in Indian journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural orifice transluminal endoscopic surgery: history and current development.Clinical endoscopy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural orifice scarless cosmetic surgeries are becoming a reality with the increasing experience of advanced laparoscopic surgeries and the availability of modern energy sources. Many techniques of minimally invasive video-assisted thyroidectomy through cervical and extra-cervical routes such as chest wall, trans axillary, submental, post-auricular, and trans-luminal approach have been attempted. However, trans-oral trans-vestibular endoscopic thyroidectomy with its excellent cosmetic effect and minimal side effects has become the more popular option among the surgical community. In this case series, we present 11 patients operated via natural orifice trans-oral, trans-vestibular endoscopic thyroidectomy approach (NO-TOTVET) by the same surgical team. From November 2022 to July 2023, NO-TOTVET was performed for 11 consecutive patients presenting with goiter to the Department of General Surgery, Command Hospital Eastern Command Kolkata. Surgery was performed using a 10-mm midline port inserted opposite incisors and two 5-mm ports inserted opposite to the left and right canine in the gingivo-buccal sulcus. NO-TOTVET was completed successfully through these ports without converting to open thyroidectomy. The demographic data and surgical outcomes of the patients were retrospectively analyzed. Eleven patients with a mean age of 37.5 ± 10.4 years were incorporated into this study. Three patients presented with papillary thyroid micro-carcinomas, and eight presented with benign nodules. A total of six hemithyroidectomies and five near-total thyroidectomies were done. All surgeries were performed successfully without conversion to open thyroidectomy. The mean operating time was 138.8 ± 33.2 min, and the average hospital stay was 1.5 days. Two patients developed seroma, and one patient had cutaneous burns. Transient recurrent laryngeal nerve paralysis was observed in one patient. There was no evidence of postoperative bleeding, infection, tetany, or any other complications. NO-TOTVET is a safe and effective technique in the hands of a trained surgeon and is a viable alternative to open thyroidectomy. It is a true scarless surgery with advantages like decreased hospital stay and minimal complications. This case series adds to the literature the scenarios and technique in which NO-TOTVET can be utilized, thus adding to the repertoire of the operating surgeon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.